Tella, Inc. reported consolidated earnings results for the six months ended June 30, 2013. For the period, the company reported net sales of JPY 865 million compared to JPY 808 million a year ago. This was attributable to firm sales in the Cell Therapy Support Business. Earnings benefited from higher sales in the Cell Therapy Support Business but were held down by lower sales in the Cell Therapy Technology Development Business and expenses associated with the growth strategy. Operating income was JPY 142 million compared to JPY 160 million a year ago. Ordinary income was JPY 132 million compared to JPY 156 million a year ago. Net income was JPY 46 million or JPY 3.45 per diluted share compared to JPY 63 million or JPY 4.79 per diluted share a year ago. Income before income taxes and minority interests was JPY 132.362 million compared to JPY 146.482 million a year ago. Income before minority interests was JPY 78.076 million compared to JPY 80.015 million a year ago. Net cash provided by operating activities was JPY 112.885 million compared to JPY 183.478 million a year ago. Purchase of property, plant and equipment was JPY 11.521 million compared to JPY 77.038 million a year ago. Purchase of intangible assets was JPY 20 million compared to JPY 27.560 million a year ago.

For the year ending December 31, 2013, the company expects consolidated net sales of JPY 1,717 million, operating income of JPY 155 million, ordinary income of JPY 100 million and net income of JPY 21 million or JPY 1.64 per share compared to previous forecast of net sales of JPY 1,684 million, operating income of JPY 95 million, ordinary income of JPY 89 million and net income of JPY 20 million or JPY 1.58 per share.